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Abstract 
Background: Calcium‑activated chloride channels (CaCCs) activation induces membrane depolarization by increas‑
ing chloride efflux in primary sensory neurons that can facilitate action potential generation. Previous studies suggest 
that CaCCs family members bestrophin‑1 and anoctamin‑1 are involved in inflammatory pain. However, their role in 
neuropathic pain is unclear. In this investigation we assessed the involvement of these CaCCs family members in rats 
subjected to the L5/L6 spinal nerve ligation. In addition, anoctamin‑1 and bestrophin‑1 mRNA and protein expression 
in dorsal root ganglion (DRG) and spinal cord was also determined in the presence and absence of selective inhibitors.
Results: L5/L6 spinal nerve ligation induced mechanical tactile allodynia. Intrathecal administration of non‑selective 
CaCCs inhibitors (NPPB, 9‑AC and NFA) dose‑dependently reduced tactile allodynia. Intrathecal administration of 
selective CaCCs inhibitors (T16Ainh‑A01 and CaCCinh‑A01) also dose‑dependently diminished tactile allodynia and 
thermal hyperalgesia. Anoctamin‑1 and bestrophin‑1 mRNA and protein were expressed in the dorsal spinal cord and 
DRG of naïve, sham and neuropathic rats. L5/L6 spinal nerve ligation rose mRNA and protein expression of anoc‑
tamin‑1, but not bestrophin‑1, in the dorsal spinal cord and DRG from day 1 to day 14 after nerve ligation. In addi‑
tion, repeated administration of CaCCs inhibitors (T16Ainh‑A01, CaCCinh‑A01 or NFA) or anti‑anoctamin‑1 antibody 
prevented spinal nerve ligation‑induced rises in anoctamin‑1 mRNA and protein expression. Following spinal nerve 
ligation, the compound action potential generation of putative C fibers increased while selective CaCCs inhibitors 
(T16Ainh‑A01 and CaCCinh‑A01) attenuated such increase.
Conclusions: There is functional anoctamin‑1 and bestrophin‑1 expression in rats at sites related to nociceptive pro‑
cessing. Blockade of these CaCCs suppresses compound action potential generation in putative C fibers and lessens 
established tactile allodynia. As CaCCs activity contributes to neuropathic pain maintenance, selective inhibition of 
their activity may function as a tool to generate analgesia in nerve injury pain states.
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nerve ligation
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Background
Neuropathic pain occurs as a direct consequence of 
either a lesion or disease affecting the somatosensory 
system [1]. Under such conditions, pain can be sponta-
neously elicited by either normally innocuous stimuli 
(allodynia) or by noxious stimuli (hyperalgesia) [2–4]. 
These conditions stem from enhanced sensory excitabil-
ity. They are attributable to peripheral or central sensi-
tization caused by either increased synaptic excitation, 
decreased synaptic inhibition (disinhibition), increased 
neuronal responsiveness, or any combination thereof 
[5]. An important component in nerve injury-induced 
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hypersensitivity is pain-related information amplifica-
tion resulting from expression and modulation of spe-
cific ion channels in the periphery and spinal dorsal horn 
[6]. However, the molecular mechanisms underlying this 
plasticity are not fully understood.
Calcium-activated chloride channels (CaCCs) include 
anoctamins, also known as TMEM16 (Ano-1 to Ano-10) 
[7–9] and bestrophins (Best-1 to Best-3) [10–12] families. 
Anoctamins and bestrophins are widely expressed in a 
host of tissues, which suggests their involvement in mul-
tiple physiological functions. Indeed, CaCCs participate 
in phototransduction, olfactory transduction, smooth 
muscle contraction, epithelial secretion and neuronal 
excitability [13–18]. Regarding the latter, anoctamins 
[19–21] and bestrophins [22–24] are present in sensory 
neurons and their activation, by an increase in intracellu-
lar Ca2+, elicits chloride efflux [13, 15, 25, 26]. Therefore, 
it has been suggested that CaCCs may promote depo-
larization of nociceptive terminals and they might be a 
key factor in the generation of action potentials [27]. In 
support of this idea, electrophysiological studies demon-
strated that anoctamin-1 augments excitability and con-
tributes to depolarization of dorsal root ganglia (DRG) 
neurons [19–21], while sciatic nerve axotomy enhances 
bestrophin-1 expression and calcium-activated chloride 
currents in DRG neurons [23, 28] suggesting the partici-
pation of CaCCs in neuropathic pain. Accordingly, it has 
been reported that anoctamin-1 ablation reduces nocic-
eptive behavior after spared nerve injury [21]. However, 
so far there has not been any systematic evaluation about 
the role of CaCCs in spinal nerve injury-induced neurop-
athy. Accordingly, we report here on the role of CaCCs in 
neuropathic pain induced by L5/L6 spinal nerve ligation.
Methods
Animals
Adult female Wistar rats (140–160  g, 6–7  weeks) from 
our own breeding facilities were used in this study. 
Female rats were used based on the fact that previous 
studies from our laboratory have found no differences 
in tactile allodynia between female and male rats [29]. 
These animals were housed in a controlled environment, 
on a 12-h light/dark cycle, with free access to food and 
water. All experiments were conducted according to the 
National Institutes of Health Guide for Care and Use 
of Laboratory Animals (Publication No. 85-23, revised 
1985), Guidelines on Ethical Standards for Investigation 
of Experimental Pain in Animals [30] and were approved 
by our local Ethics Committee (Protocol 0042-13, Cin-
vestav, Mexico City, Mexico). In addition, every effort 
was made to minimize pain and suffering, and the num-
ber of rats used was the least required to obtain signifi-
cant statistical power.
Induction of nerve injury and measurement of tactile 
allodynia
Neuropathic pain was induced by spinal nerve ligation 
[31]. Briefly, rats were anesthetized with a mixture of ket-
amine (50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After 
surgical preparation and exposure of the dorsal vertebral 
column, the left L5 and L6 spinal nerves were exposed 
and tightly ligated with 6-0 silk suture distal to the DRG. 
For sham-operated rats, the nerves were exposed but 
not ligated. Rats exhibiting motor deficiency such as paw 
dragging were discarded from the study.
Tactile allodynia was determined as previously 
described [32]. Fourteen days after surgery, animals 
were placed in cages with a mesh grid floor and allowed 
to acclimate for a minimum of 30  min before perform-
ing the experiment. Von Frey filaments (Stoelting, Wood 
Dale, IL, USA) were used to determine the 50% paw with-
drawal threshold using the up-down method of Dixon 
[33]. A series of filaments, starting with one that had a 
buckling weight of 2  g, were consecutively applied in 
consecutive sequence to the plantar surface of the right 
hind paw with a pressure causing the filament to buckle. 
Lifting of the paw indicated a positive response and 
prompted the use of the next weaker filament, whereas 
absence of paw withdrawal after 5  s indicated a nega-
tive response and prompted the use of the next heavier 
filament in a series. This paradigm continued until four 
more measurements were made after the initial change 
of the behavioral response or until five consecutive nega-
tive (assigned a score of 15 g) or four consecutive posi-
tive (assigned a score of 0.25 g) responses occurred. The 
resulting scores were used to compute the 50% with-
drawal threshold by using the formula: 50% g thresh-
old = 10(Xf +κδ)/10,000, where Xf = value (in log units) of 
the final von Frey filament used, κ = the value from table 
published by Dixon [33] for the pattern of positive and/or 
negative responses, and δ =  the mean difference (in log 
units) between stimulus strengths. Allodynia was consid-
ered to be present when paw withdrawal thresholds were 
less than 4 g.
Thermal hyperalgesia
The Hargreaves test measured the latency to radiant heat 
using a paw thermal stimulator [34]. Briefly, rats were 
placed individually in Plexiglass cubicles and allowed to 
acclimate for 20–30 min before the experiment. A radi-
ant heat stimulus was applied to the base of the paw as it 
rested on a glass plate maintained at 30 ± 0.1°C at 0, 1, 2, 
4, 6 and 8 h after drug administration. A timer was auto-
matically actuated when the light source was turned on. 
The response latency was defined as the time required 
for abrupt withdrawal of the paw. In all cases, a cut-off 
of 20 s was employed to avoid tissue injury. Each test was 
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repeated three times and the average paw withdrawal 
latency was calculated based on three measurements.
Assessment of motor activity
Motor coordination was assessed in the Rotarod system 
[35]. Animals were acclimated 2  days before evaluation 
by walking them each day on an accelerating Rotarod 
apparatus (Panlab Harvard Apparatus, Barcelona, Spain). 
On the third day, animals were tested starting 1.5  h 
before and immediately after drug administration as well 
as 1.5 and 3 h later (time of peak drug effect). Evaluation 
was carried out with an acceleration from 4 to 40 rpm in 
10 min. Motor coordination was considered as the time 
latency to fall off the Rotarod apparatus. It was deter-
mined from the mean time in three trials for each rat at 
each time.
Spinal catheterization
Seven days after spinal nerve ligation surgery, rats were 
again anesthetized with a ketamine (50 mg/kg, i.p.) and 
xylazine (10  mg/kg, i.p.) combination and placed in a 
stereotaxic head holder in order to expose the atlanto-
occipital membrane [36]. After piercing the membrane, 
a PE-10 catheter (7.5 cm) was passed intrathecally to the 
level of the thoracolumbar junction and the wound was 
sutured. Rats were allowed to recover from surgery for 
7 days in individualized cages before use. Animals show-
ing any signs of motor impairment were eliminated from 
the study and euthanized with a CO2 chamber.
Semi‑quantitative reverse transcription‑polymerase  
chain reaction
Total RNA from ipsilateral (injured side) dorsal spi-
nal cord segments L1–S1 as well as ipsilateral DRG 
(L4–L6) were isolated by the guanidinium-thiocyanate 
method with TRIzol-reagent according to the manu-
facturer’s instructions (Invitrogen Corporation, Carls-
bad, CA, USA). The concentration and purity of the 
RNA were determined by measuring the absorbance at 
260 and 280  nm in a NanoDrop ND-2000 spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE, 
USA). Equal amounts (5 μg) of RNA from samples were 
reversed-transcribed into first-strand complementary 
DNA (cDNA) using oligo dT and M-MLV-reverse tran-
scriptase (Invitrogen Corporation, Carlsbad, CA, USA). 
The reaction was performed at 37°C for 60 min, followed 
by a heat denaturation step at 95°C for 5  min. Amplifi-
cation of cDNA by polymerase chain reaction (PCR) was 
performed with specific primers previously reported [23] 
for bestrophin-1 (forward, 5′-TGGCAGAACAGCTC 
ATCAAC-3′ and reverse, 5′-GCTGCCTCGTTCCAGT 
ACAT-3′, 100  bp product) and anoctamin-1 (forward, 
5′-TTCGTCAATCACACGCTCTC-3′ and reverse, 
5′-GGGGTTCCCGGTAATCTTTA-3′, 100 bp product). 
The reaction mixture contained 2.5 mM MgCl2, 200 μM 
dNTP, 1 U Taq DNA polymerase (Invitrogen Corpora-
tion, Carlsbad, CA, USA), 100  pmol of specific sense 
and antisense primers for each gene, and 10 ng of first-
strand cDNA in a total volume of 50  μL. The optimal 
number of cycles within the linear range of amplifica-
tion was selected. The PCR conditions for amplification 
were 94°C for 5 min. Thirty-five cycles of 94°C for 45 s, 
58.5°C for 45 s, 72°C for 90 s, and 72°C for 7 min using 
a Mastercycler DNA Engine Thermal Cycler (Eppendorf, 
Hamburg, Germany). To ensure that equal amounts of 
reverse-transcribed RNA were added to the PCR, the 
β-actin housekeeping gene was amplified using oligo-
nucleotides previously reported [37]. The PCR products 
were analyzed by 10% SDS–polyacrylamide gel electro-
phoresis and ethidium bromide staining and captured by 
a Chemidoc XRS +  imaging system (BioRad, Hercules, 
CA, USA). Bands were quantified by scanning densitom-
etry using Image Lab 5.0 software (BioRad, Hercules, CA, 
USA).
Western blotting
Ipsilateral dorsal spinal cord segments L1–S1 and DRG 
(L4–L6) were homogenized in ice-cold lysis buffer 
(150  mM NaCl, 50  mM Tris, 1  mM EDTA, 1% NP40, 
0.1% SDS, 2 mM phenyl-methyl-sulfonyl fluoride, 6.8 µg/
mL aprotinin, 4  µg/mL leupeptin, 4  µg/mL pepstatin A, 
4  µg/mL soybean trypsin inhibitor and 2  mM NaVO4) 
[35]. Homogenates were centrifuged at 4°C for 10  min 
at 14,000  rpm, and the supernatant fraction was used 
to measure protein concentration [38]. Total protein 
(50 or 100  µg, for spinal cord or DRG, respectively) was 
resolved by 10% SDS–polyacrylamide gel electrophoresis 
and transferred to polyvinylidene difluoride membranes. 
Membranes were blocked with 5% non-fat milk in phos-
phate-buffered saline at pH 7.4 containing (in mM) (137 
NaCl, 2.7 KCl, 10 Na2HPO4 and 2 KH2PO4) with Tween 
0.05% and they were incubated at 4°C overnight with rab-
bit anti-bestrophin-1 (ABC-001, 1:200; Alomone Labs, 
Jerusalem, Israel) or rabbit anti-anoctamin-1 (ACL-011, 
1:100; Alomone Labs, Jerusalem, Israel). Horseradish per-
oxidase-conjugated secondary antibody (anti-rabbit, 711-
035-152, 1:6,000; Jackson ImmunoResearch Laboratories 
Inc, West Grove, PA, USA) was applied for detecting the 
primary antibody signal using an enhanced chemilumines-
cence detection system according to the manufacturer´s 
instructions (Western Lightning Ultra, NEL112001EA, 
PerkinElmer, Waltham, MA, USA). After bestrophin-1 
or anoctamin-1 detection, the membranes were stripped, 
blocked and incubated with a mouse monoclonal anti-
body directed against β-actin (MAB1501, 1:10,000; Mil-
lipore, Billerica, MA, USA) and its respective horseradish 
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peroxidase-conjugated secondary antibody (anti-mouse, 
115-035-003, 1:10,000; Jackson ImmunoResearch Labora-
tories Inc, West Grove, PA, USA). β-actin expression was 
used as a loading control to normalize protein expression 
levels. In addition, antibodies were pre-adsorbed with con-
trol bestrophin-1 and anoctamin-1 peptides to validate 
antibody specificity. Scanning of the immunoblots was 
performed and the bands were quantified by densitometry 
using an image analysis program (LabWorks; UVP Inc., 
Upland, CA, USA).
Tissue preparation and recording of compound action 
potential
Rats were anesthetized with a mixture of ketamine 
(50  mg/kg, i.p.) and xylazine (10  mg/kg, i.p.) 14  days 
after surgery. A laminectomy was performed while the 
surgical field was bathed with oxygenated (5% CO2 and 
95% O2) artificial cerebrospinal fluid (CSF) at pH of 
7.6 containing (in mM): 117 NaCl, 3.6 KCl, 1.2 MgCl2, 
2.3 CaCl2, 1.2 NaH2PO4, 25 NaHCO3 and 11 glucose 
at room temperature. The L5 ganglia attached to dor-
sal root and spinal nerve were removed. The tissue was 
transferred to a recording chamber and bathed with 
artificial CSF solution at room temperature.
To evoke action potentials, electrical stimulation 
(0.3  ms of duration) was applied to the peripheral cut 
end of the spinal nerve with a suction electrode. The 
compound action potential (CAP) was recorded in the 
dorsal root with a suction electrode. The recording elec-
trode was connected to a DC amplifier (World Preci-
sion Instruments, Sarasota, FL, USA) with a bandwidth 
of DC to 10 kHz. Unless otherwise noted, the recordings 
shown represent the average of 10 stimuli applied every 
10 s. The threshold (T) of the faster Aα/β fiber compound 
action potential (CAP) was determined by increasing 
the stimulus strength until a visible action potential was 
evoked 50% of the time. The maximal CAP of the puta-
tive C fibers was evoked stimulating at 50xT.
Drugs
5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB), 
anthracene-9-carboxylic acid (9-AC) and niflumic acid 
(NFA) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The specific anoctamin-1 inhibitor (T16Ainh-
A01) was purchased from Tocris Bioscience (Avon, Bristol, 
England). The specific calcium-activated chloride channel 
inhibitor (CaCCinh-A01) was purchased from Merck Milli-
pore (Billerica, MA, USA). All drugs were dissolved in 30% 
dimethyl sulfoxide (DMSO) in all doses tested.
Experimental design
In order to determine the role of CaCCs in neuropathic 
pain, neuropathic (14 days after spinal nerve ligation) and 
sham animals received an intrathecal (10 μL) or periph-
eral (into the dorsal surface of the left hind paw, 50 μL) 
injection of vehicle (30% DMSO) or increasing concen-
trations of non-selective (NPPB, 9-AC or NFA) or selec-
tive (T16Ainh-A01 or CaCCinh-A01) CaCCs inhibitors 
5  min before evaluation of tactile allodynia, thermal 
hyperalgesia or motor coordination. The antiallodynic 
and antihyperalgesic effects were evaluated for the fol-
lowing 8  h. All behavioral tests were scored by a single 
investigator who was blind to the treatment received by 
the subject. Furthermore, in order to assess the role of 
the CaCCs bestrophin-1 and anoctamin-1 in neuropathic 
rats, we determined the expression of bestrophin-1 and 
anoctamin-1 mRNA and protein levels in the ipsilateral 
dorsal section of the spinal cord and ipsilateral DRG at 1, 
7 and 14 days after nerve injury.
As spinal nerve ligation increased anoctamin-1 expres-
sion, we next determined its anoctamin-1 mRNA and 
protein expression in the presence and absence of the 
most effective CaCCs inhibitors. For this, we intrathe-
cally administered CaCCinh-A01 (10  μg), T16Ainh-A01 
(10 μg) or NFA (300 μg) every 6 h for five times starting 
on day 12 after ligation. Samples of spinal cord and DRG 
were obtained on day 14 after nerve ligation.
Considering that bestrophin-1 mRNA or protein 
expression levels were not modified by spinal nerve liga-
tion and the lack of specific inhibitors for this channel, 
we next determined bestrophin-1 mRNA and protein 
expression in the presence and absence of its specific 
antibody. For this study, we intrathecally injected either 
the anti-bestrophin-1 or anti-anoctamin-1 antibody 
(2  μg) every 6  h for five times starting on day 12 after 
ligation, as previously reported for other proteins [39–
41]. Withdrawal threshold was evaluated every 6 h after 
each administration and rats were sacrificed on day 14 
after nerve ligation to obtain spinal cord and DRG.
To investigate whether the antiallodynic effect of 
CaCCs inhibitors was mediated by a reduction of the 
peripheral nerve injury-induced hyperexcitability, we 
recorded the C component of the CAP in L5 dorsal roots 
of naïve, sham and neuropathic rats in the presence and 
absence of the selective CaCCs inhibitors T16Ainh-A01 
(20 μM) and CaCCinh-A01 (20 μM).
Data analysis and statistics
All behavioral results are reported as the mean ±  SEM 
for six animals/group. Curves were constructed by plot-
ting the paw withdrawal threshold or withdrawal latency 
as a function of time. An increase of the 50% withdrawal 
threshold or withdrawal latency was considered as antial-
lodynic or antihyperalgesic effect, respectively.
In order to determine the dose required to reduce 50% 
of the possible maximal effect (ED50), we calculated the 
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percent of maximum possible effect (%MPE) according to 
the following equation:
where AUC is the area under the curve of the time-






(AUCsham − AUCvehicle))× 100
group. The dose–response curves were constructed by 
plotting the %MPE versus dose and the experimental 
points were fitted using least-square linear regression. 
ED50 ± standard error (SE) was calculated according to 
Tallarida [42].
For mRNA and protein expression, all results are 
reported as the mean relative intensity ± SEM for three 
independent animals/group.























































































































Figure 1 Intrathecal injection of non‑selective CaCCs inhibitors reduces tactile allodynia. Time‑course of the antiallodynic effect of NPPB (300 μg, 
a), 9‑AC (300 μg, c) and NFA (300 μg, e) in rats subjected to L5/L6 spinal nerve ligation. Withdrawal threshold was assessed 14 days after spinal 
nerve injury. Dose–response relationship of the antiallodynic effect of NPPB (30–300 μg, b), 9‑AC (10–300 μg, d) and NFA (10–300 μg, f) in spinal 
nerve injured rats compared to sham (S) and vehicle (V) groups. Data are presented as the mean ± SEM for six animals. Note that non‑selective 
CaCCs inhibitors significantly increased withdrawal threshold as well as the % of maximum possible effect (%MPE). *Significantly different from the 
vehicle group (p < 0.05), as determined by one‑way ANOVA followed by the Student–Newman–Keuls test.
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For the electrophysiological recordings, all results are 
reported as the mean of the normalized area under the 
curve of the C component of the CAP  ±  SEM for six 
animals/group.
Statistical differences between two groups were 
determined by the Student t test. One- or two-way 
analysis of variance (ANOVA), followed by Student–
Newman–Keuls or Bonferroni test, were used to 
compare differences between more than two groups. 
Differences were considered to reach statistical signifi-
cance when p < 0.05.
Results
CaCCs inhibitors reverse tactile allodynia in spinal nerve 
ligated rats
Ligation of L5/L6 spinal nerves reduced the 50% paw 
withdrawal threshold response in the ipsilateral paw, as 
compared to the sham-operated rats, which is indica-
tive of tactile allodynia induction (Figure 1a, c, e; [29]). 
On the other hand, 14 days after nerve injury intrathe-
cal administration of the non-selective CaCCs inhibi-
tors NPPB, 9-AC or NFA (Figure  1a, c, e), but not 
vehicle, significantly (p  <  0.05) reversed dose-depend-
ently this condition in neuropathic rats (Figure  1b, d, 
f ). Furthermore, spinal, but not peripheral (Additional 
file  1: Fig. S1), administration of the selective CaCCs 
inhibitors T16Ainh-A01 and CaCCinh-A01 (Figure  2a, 
c) had effects similar to those induced by the afore-
mentioned non-specific inhibitors (Figure 2b, d). These 
declines elicited by the CaCCs inhibitors did not occur 
in sham-operated rats (Additional file  2: Fig. S2). The 
maximal antiallodynic effect of these inhibitors in all 
cases occurred about 2  h after their administration 
and then decayed gradually in about 8 h. Non-selective 
CaCCs inhibitors produced a maximal decline of about 
65% while the selective CaCCs inhibitors effect reached 
about 80% of the maximal possible fall. Table 1 lists the 
ED50 of all inhibitors used. 
CaCCs inhibitors reverse thermal hyperalgesia in spinal 
nerve ligated animals
Besides tactile allodynia, ligation of L5/L6 spinal nerves 
caused a significant decrease in the withdrawal latency 
time produced by a thermal stress in the ipsilateral, but 
















































































Figure 2 Intrathecal injection of selective CaCCs inhibitors reduces tactile allodynia. Time‑course of the antiallodynic effect of T16Ainh‑A01 (10 μg, 
a) and CaCCinh‑A01 (10 μg, c) in rats subjected to L5/L6 spinal nerve injury. Withdrawal threshold was assessed 14 days after spinal nerve injury. 
Dose–response relationship of the antiallodynic effect of T16Ainh‑A01 (0.01–10 μg, b) and CaCCinh‑A01 (0.01–10 μg, d) in spinal nerve injured 
rats compared to sham (S) and vehicle (V) groups. Data are presented as the mean ± SEM for six animals. Note that selective CaCCs inhibitors 
significantly increased withdrawal threshold as well as the % of maximum possible effect (%MPE). *Significantly different from the vehicle group 
(p < 0.05), as determined by one‑way ANOVA followed by the Student–Newman–Keuls test.
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not contralateral (data not shown), paw of all rats as com-
pared to the naïve or sham-operated animals. On the 
other hand, intrathecal administration (on day 14th) of 
either NFA (300  µg), T16Ainh-A01 (10  µg) or CaCCinh-
A01 (10  µg), but not vehicle, significantly increased the 
withdrawal latency time in the ligated animals (Figure 3). 
The maximal antihyperalgesic effect in all cases occurred 
in approximately 2 h after drug administration and then 
decayed gradually in about 8 h.
Expression of bestrophin‑1 and anoctamin‑1 in spinal 
nerve injured rats
PCR and western blot analysis of the ipsilateral dorsal 
spinal cord and DRG demonstrated bestrophin-1 (Fig-
ure 4) and anoctamin-1 (Figure 5) mRNA and protein 
expression, in naïve, sham and ligated rats. Western 
blots resolved bands of about 68 and 90  kDa for bes-
trophin-1 (Additional file  3: Figure S3A) and anoc-
tamin-1 (Additional file  3: Figure S3B), respectively. 
On the other hand, immunoreactive bands for both 
proteins were absent when the primary antibodies 
were pre-adsorbed with the corresponding antigenic 
peptides (Additional file 3: Figure S3). 
Spinal nerve ligation neither modified bestrophin-1 
mRNA and protein expression in the ipsilateral dorsal 
region of the spinal cord nor in the DRG, as compared 
to naïve or sham-operated rats (Figure  4). In marked 
contrast, nerve injury increased (p < 0.05) anoctamin-1 
mRNA and protein expression in the dorsal region of 
the spinal cord and DRG from day 1 to 14 (Figure 5).
CaCCs inhibitors blunt neuropathy‑induced rises 
on bestrophin‑1 and anoctamin‑1 mRNA and protein 
expression
Repeated intrathecal injection (five times, every 6 h start-
ing on day 12 after nerve injury) of CaCCinh-A01 (10 μg), 
T16Ainh-A01 (10 μg) or NFA (300 μg), but not vehicle, 
prevented nerve injury-induced rises in anoctamin-1 
mRNA (Additional file  4: Figure S4) and protein (Fig-
ure 6) expression in the dorsal spinal cord and DRG on 
day 14 after nerve injury.
Since spinal nerve injury-failure to increase bestro-
phin-1 expression, we evaluated its involvement in 
Table 1 Effective doses of  the non-selective and  selective 
CaCCs inhibitors in  spinal nerve injury-induced tactile allo-
dynia. Drugs were administered as  a post-treatment. Data 
were collected from  the ipsilateral paw 14 days after  spinal 
nerve ligation. Data are presented as the mean (n = 6) ± SEM.
Inhibitor ED50 (µg)
NPPB 183.2 ± 4.9
9AC 132 ± 46.7
NFA 109.9 ± 3.8
T16Ainh‑A01 1.8 ± 0.3
CaCCinh‑A01 0.4 ± 0.1


































Figure 3 Intrathecal injection of non‑selective and selective CaCCs inhibitors reduces thermal hyperalgesia. Time‑course of the antihyperalgesic 
effect of NFA (300 μg), T16Ainh‑A01 (10 μg) and CaCCinh‑A01 (10 μg) in rats subjected to L5/L6 spinal nerve injury compared to naïve, sham and 
vehicle groups. Withdrawal latency was assessed 14 days after spinal nerve injury. Data are presented as the mean ± SEM for six animals deter‑
mined by the mean of three trials for each rat at each time. Note that CaCCs inhibitors increased withdrawal latency. *Significantly different from the 
vehicle group (p < 0.05), as determined by repeated measures two‑way ANOVA followed by the Bonferroni test.
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neuropathic pain induction by instead injecting a func-
tion blocking specific antibody. Repeated intrathecal 
anti-bestrophin-1 or anti-anoctamin-1 antibody adminis-
tration (five times, 2 μg/6 h starting on day 12 after nerve 
injury), but not vehicle, reversed established tactile allo-
dynia (Figure 7a, d) and this effect was accompanied with 
a decline of its respective mRNA (Additional file 5: Figure 
S5) and protein (Figure 7) expression in the dorsal spinal 
cord and DRG on day 14 after spinal nerve ligation.
Nerve ligation induced changes in compound action 
potential (CAP) size and conduction velocity
In previous studies of mammalian DRG neurons using 
sharp or patch microelectrodes, action potential dura-
tion tended to increase after axotomy [43]. Here, we 
recorded the C component of the CAP in the dorsal root 
attached to its ganglion after peripheral stimulation at 
the spinal nerves (Figure 8a). Area under the curve of the 
C component of the CAP recorded in neuropathic rats 
increased in comparison to naïve or sham-operated rats 
(Figure 8b). Moreover, its conduction velocity was slowed 
(data not shown).
Effect of CaCCs blockers on the C component of the CAP
Like other ion channels, CaCCs regulate the excitability 
of neurons [13]. Application of T16Ainh-A01 [20  μM] 
and CaCCinh-A01 [20 μM] did not modify the C com-
ponent of the CAP in the naïve animal preparation (Fig-
ure  9a, b). In sharp contrast, these drugs significantly 
(p < 0.05) reduced the nerve injury-induced rise in the 
C component of the CAP (Figure  9c, d). These results 
along with behavioral and molecular studies described 
above suggest that declines in neuropathic pain induced 
by CaCCs inhibitors stem from their effects on the 
action potential of nociceptive primary afferents.
Assessment of motor coordination
Intrathecal administration of either NFA or T16Ainh-A01 
and CaCCinh-A01 did not affect motor coordination on 
the Rotarod apparatus (Figure  10) at the same dosages 
and times in which they produced the greatest antiallo-
dynic or antihyperalgesic effects.
Discussion
Our study is the first one to demonstrate that intrath-
ecal administration of both non-selective and selective 
CaCCs inhibitors reduces tactile allodynia and thermal 
hyperalgesia in neuropathic rats caused by L5/L6 spi-
nal nerve ligation. First, we found that the non-selective 
CaCCs inhibitors NPPB, 9-AC and NFA reversed in a 
dose-dependent manner tactile allodynia. Since these 
drugs block endogenous CaCCs in  vitro [44–47], our 
data suggest that functional CaCCs participate in the 
maintenance of neuropathic pain in rats. However, these 
drugs are non-specific and also block volume-regulated 
anion channels [48] and K+ channels in  vitro [49]. To 
further assess the role of CaCCs in neuropathic pain, we 
next used the selective anoctamin-1 inhibitor T16Ainh-
A01 [50, 51] as well as the selective CaCCs inhibi-
tor CaCCinh-A01 [51, 52]. These drugs also reversed 
the established tactile allodynia in neuropathic rats. 
Moreover, NFA, T16Ainh-A01 or CaCCinh-A01 reduced 
thermal hyperalgesia. These data strongly suggest that 

























































































Figure 4 Bestrophin‑1 is expressed in the spinal cord and DRG. RT‑
PCR (a, b) and western blot (c, d) analysis of bestrophin‑1 (Best‑1) at 
the ipsilateral dorsal portion of the spinal cord (SC) and DRG obtained 
from naïve (Na), sham (S) and spinal nerve ligated (SNL) rats. Insets 
show a representative band of the PCR product (upper panels) and 
immunoblot (lower panels) obtained with the specific bestrophin‑1 
and β‑actin primers or antibodies, respectively. Data were normal‑
ized against β‑actin and are expressed as the mean ± SEM of three 
independent rats. Note that spinal nerve injury did not modify Best‑1 
mRNA and protein expression.
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CaCC activation contributes to tactile allodynia and 
thermal hyperalgesia expression. Our data agree with 
a previous mouse study showing that functional anoc-
tamin-1 ablation reduces spared nerve injury-induced 
mechanical allodynia and thermal hyperalgesia [21]. 
Furthermore, our results also indicate that another 
CaCC, bestrophin, is activated and contributes to neu-
ropathic pain symptomology.
The antiallodynic effectiveness of the CaCCs inhibi-
tors was inversely related to their target selectivity. 
Namely, the selective anoctamin-1 inhibitor T16Ainh-
A01 was less effective than CaCCinh-A01, which inhibits 
anoctamin-1 and other CaCCs, suggesting that acti-
vation of other CaCCs besides anoctamin-1 contrib-
ute to inducing neuropathic pain. These results agree 
with an in  vitro study indicating that CaCCinh-A01 is 
a more broad spectrum chloride current inhibitor due 
to its effectiveness at inhibiting currents mediated by 
bestrophin-1 and anoctamin-1 activation-1 [51]. On 
the other hand, T16Ainh-A01 is less effective since it 
selectively inhibited chloride currents solely mediated 
by anoctamin-1 [51, 52]. Other studies demonstrated 
that local peripheral administration of NFA, NPPB or 
CaCCinh-A01 produced antinociception in rats injected 
with bradykinin, formalin and carageenan [19, 21, 24]. 
These data also suggest that CaCCs activation partici-
pates in inducing inflammatory pain in rats. Similarly, 
another indication of CaCC involvement in eliciting 
neuropathic pain is that bradykinin-induced increases 
in Ca2+-activated chloride currents were prevented by 




































































































Figure 5 Spinal nerve injury increases anoctamin‑1 expression in 
the spinal cord and DRG. RT‑PCR (a, b) and western blot (c, d) analysis 
of anoctamin‑1 (Ano‑1) at the ipsilateral dorsal portion of the spinal 
cord (SC) and DRG obtained from naïve (Na), sham (S) and spinal 
nerve ligated (SNL) rats. Data were normalized against β‑actin and 
are expressed as the mean ± SEM of three independent rats. Insets 
show a representative band of the PCR product (upper panels) and 
immunoblot (lower panels) obtained with the specific anoctamin‑1 
and β‑actin primers or antibodies, respectively. *Significantly differ‑
ent from the S group (P < 0.05), #significantly different from the Na 
group (P < 0.05), as determined by one‑way ANOVA, followed by the 
Student–Newman–Keuls test. Note that spinal nerve injury enhanced 
Ano‑1 mRNA and protein expression in spinal cord and DRG whereas 
that surgery increased Ano‑1 expression in sham (S) animals in spinal 







































































Figure 6 CaCCs inhibition reverses spinal nerve injury‑induced rise 
in anoctamin‑1 expression. Western blot analysis of anoctamin‑1 
(Ano‑1) at the ipsilateral dorsal portion of the spinal cord (SC, a) and 
DRG (b) obtained from neuropathic rats with repeated intrathe‑
cal administration of vehicle (V), CaCCinh‑A01, T16Ainh‑A01 or NFA. 
Data were normalized against β‑actin and are expressed as the 
mean ± SEM of three independent rats. Insets in a and b show a 
representative blot obtained with anoctamin‑1 and β‑actin primary 
antibodies. *Significantly different from the V group (p < 0.05), as 
determined by one‑way ANOVA, followed by the Student–New‑
man–Keuls test. Note that CaCCs inhibitors reduced spinal nerve 
injury‑induced rise in anoctamin‑1 expression.
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CaCCs inhibitors or siRNA CaCC knockdown [19, 23, 
28].
As reported, we found bestrophin-1 and anoctamin-1 
mRNA and protein expression in the DRG of naïve 
rats [19–24]. Furthermore, our results indicate their 
presence also in the spinal cord. mRNA and protein 
expression of anoctamin-1 was selectively enhanced 
by spinal nerve ligation in the dorsal spinal cord and 
DRG suggesting its involvement in neuropathic pain. 
This possibility was validated based on our finding that 
NFA, T16Ainh-A01 and CaCCinh-A01 prevented spinal 
nerve injury-induced rise in anoctamin-1 mRNA and 
protein expression and reduced neuropathic pain. Fur-
thermore, repeated administration of the selective anti-
body against anoctamin-1 (ACL-011, 1:100; Alomone 
Labs, Jerusalem, Israel) reduced anoctamin-1 expres-
sion and tactile allodynia. These data suggest a strong 
correlation between anoctamin-1 mRNA and protein 










































































































































Figure 7 Intrathecal administration of selective antibody anti‑bestrophin‑1 or anti‑anoctamin‑1 reverses established allodynia and reduces protein 
expression. Time‑course of the antiallodynic effect of antibodies against bestrophin‑1 (Best‑1 ab, 2 μg/6 h × 30 h; a) or anoctamin‑1 (Ano‑1 ab, 
2 μg/6 h x 30 h; d) in rats subjected to L5/L6 spinal nerve ligation. Paw withdrawal threshold was assessed every 6 h starting 12 days after spinal 
nerve ligation. Data are presented as the mean ± SEM for six animals. *Significantly different from the vehicle group (p < 0.05), as determined by 
two‑way ANOVA followed by the Bonferroni test. Western blot analysis of bestrophin‑1 (Best‑1, b, c) or anoctamin‑1 (Ano‑1, e, f) at the ipsilateral 
dorsal portion of the spinal cord (SC) and DRG obtained from neuropathic rats with repeated intrathecal administration of antibodies against bes‑
trophin‑1 (Best‑1 ab) or anoctamin‑1 (Ano‑1 ab). Data were normalized against β‑actin and are expressed as the mean ± SEM of three independent 
rats. Insets in b–f show a representative blot obtained with bestrophin‑1, anoctamin‑1 and β‑actin primary antibodies. *Significantly different from 
the vehicle (V) group (p < 0.05), as determined by the Student t test.
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levels and the presence of allodynia in neuropathic rats. 
Our results agree with those of García et al. [24], who 
found that formalin increases anoctamin-1, but not 
bestrophin-1, protein expression in the rat DRG. It is 
already known that anoctamin-1 is co-expressed with 
TRPV1 and IB4 in small sensory neurons [19, 20], and 
its expression is required for inflammatory and nerve-
injury induced thermal hyperalgesia and mechanical 
allodynia in mice [21]. Taken together, anoctamin-1 
plays a pronociceptive role and it is up-regulated by 
inflammatory [20, 24] and neuropathic (this study) pain 
in rats.
Unlike us, a previous study found that axotomy solely 
increases bestrophin-1 transcript expression in mice 
DRG [23]. This discrepancy may be due to a difference 
in pain models, species, and molecular methods used 
in each study. Regarding the first point, it seems that 
axotomy or spared nerve injury increases chloride cur-
rents through enhanced bestrophin-1 expression [23, 
28]. In marked contrast, spinal nerve ligation does not 
modify its expression (our study). Preliminary experi-
ments in our laboratory confirm that spared nerve 
injury enhances bestrophin-1 expression in rats DRG 
(data not shown). It seems that axotomy or spared 
Figure 8 Illustration of the preparation and the compound action 
potential (CAP). a Left panel the L5 ganglion attached to dorsal root 
(DR) and spinal nerve was removed of naïve, sham and neuropathic 
rats. Right panel the tissue was collocated into a recording chamber. 
The spinal nerve was stimulated at 50xT to evoke maximal C fiber 
CAP recorded in the dorsal root. b Upper panel examples of maximal 
C fiber CAP recorded extracellularly from naïve (black trace), sham and 
neuropathic (red trace) rats. The bar chart in the lower panel shows the 
comparison of CAP. Note that the size of the CAP in neuropathic was 
higher than in naïve rats.
Figure 9 Effect of CaCCs inhibitors on the CAP of naïve and neuro‑
pathic rats. Upper panels examples of the CAP recorded in absence 
(control, black trace) and in presence of T16Ainh‑A01 [20 μM] (red 
trace) recorded from naïve (a) and neuropathic (c) rats. The bar charts 
below of traces show the comparison of normalized area under the C 
component of the CAP between the naïve and T16Ainh‑A01 groups. 
Note that T16Ainh‑A01 diminished the compound action potential 
in neuropathic, but not in naïve, rats. Lower panels examples of CAP 
recorded in absence (control, black trace) and in presence of CaCCinh‑
A01 [20 μM] (red traces) recorded from naïve (b) and neuropathic 
(d) rats. The bar charts below of traces compare the normalized 
area under the C component of the CAP between the control and 
CaCCinh‑A01 groups. Note that CaCCinh‑A01 decreased the CAP size 
in neuropathic, but not in naïve, rats. *Significantly different from the 
neuropathic group (p < 0.05), as determined by the Student t test.
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nerve injury increases calcium-activated chloride cur-
rents in medium- and large-, but not in small-, diam-
eter neurons displaying regenerative growth [28]. In 
line with this, bestrophin-1 is preferentially expressed 
in large and medium size neurons and its increased 
expression is closely related with nerve regrowth after 
axotomy [23]. From these data, it appears that axotomy 
causes more damage and therefore promotes greater 
nerve regeneration in comparison to spinal nerve liga-
tion. Discrepancies could also be due to the molecular 
techniques (PCR and western blot versus qPCR and 
in  situ hybridization). Although we could not detect 
any bestrophin-1 up-regulation, its expression is evi-
dent in dorsal spinal cord and DRG of ligated rats. 
Moreover, we found that administration of a specific 
anti-bestrophin-1 antibody reduced tactile allodynia 
and bestrophin-1 expression. This finding reveals that 
bestrophin-1 participates in the maintenance of neuro-
pathic pain in the spinal nerve ligation model. However, 
assigning a definitive role for bestrophin-1 in mediat-
ing neuropathic pain awaits the future development of 
selective bestrophin-1 inhibitors.
Besides the antiallodynic effect of CaCCs inhibi-
tors, we found that these drugs partially diminished 
spinal nerve ligation-induced rise in the C compo-
nent of the CAP. This finding suggests that nerve 
injury increases C-like fibers action potential ampli-
tude resulting in more neurotransmitter release at the 
dorsal horn level. The declines in central sensitization 
induced by CaCCs inhibitors appear to be associ-
ated with their diminution of amplitude enhancement 
induced by nerve injury. Our data partially agree with 
previous studies showing that inflammatory mediators 
increase anoctamin-1-mediated excitability of small 
sensory neurons [19, 21] while axotomy increases 
calcium-activated chloride currents in large-, but not 
small-, diameter neurons [23, 28]. This agreement sug-
gests that spinal nerve ligation increases spinal dorsal 
roots excitability, which is partially mediated by CaCC 
activity.
The underlying mechanisms accounting for how nerve 
injury activates CaCCs are unclear. However, it is known 
that nerve injury produces peripheral and central sensiti-
zation that in turn leads to a massive activation of excita-
tory mechanisms increasing intracellular Ca2+ levels [2]. 
This response is sufficient to activate CaCCs producing 
chloride efflux along with inward currents mediating 
membrane voltage depolarization [53] and hyperexcit-
ability, which then would lead to neuropathic pain.
In summary, the present study revealed that intrath-
ecal administration of non-selective and selective 
CaCCs inhibitors has antiallodynic and antihyper-
algesic effects in spinal nerve injured rats. There is 
bestrophin-1 and anoctamin-1 mRNA and protein 
expression in the spinal cord and DRG of neuropathic 
rats, but only anoctamin-1 is up-regulated after spi-
nal nerve injury. Selective anoctamin-1 blockade 
reversed increases in its expression induced by spi-
nal nerve injury. Furthermore, intrathecal injection of 
the selective anti-bestrophin-1 or anti-anoctamin-1 
antibody reduced its respective expression along with 
a reduction of tactile allodynia. Spinal nerve injury 
increased the C component of the CAP whereas selec-
tive CaCCs inhibitors reversed this response. These 
results strongly suggest that CaCCs, anoctamin-1 and 
bestrophin-1, participate in the maintenance of neuro-
pathic pain. The identification of CaCC activation as 
a component of neuropathic pain induction points to 
the possibility that these channels may be useful tar-
gets for treating neuropathic pain in a clinical setting.






















Figure 10 Intrathecal administration of the CaCCs inhibitors did not 
affect the motor coordination of neuropathic rats. Time‑course of the 
effect of NFA (300 μg), T16Ainh‑A01 (10 μg) or CaCCinh‑A01 (10 μg) on 
motor coordination of rats subjected to L5/L6 spinal nerve ligation 
compared to naïve, sham and vehicle groups. Rats were assessed 
on the Rotarod apparatus before and at 0, 1.5 and 3 h after drug 
administration (n = 6). Data are expressed as the latency to fall off the 
Rotarod apparatus determined by the mean of three trials for each 
rat at each time. Note that drugs did not modify motor coordination 
at any time.
Additional files
 Additional file 1: Figure S1. Local peripheral injection of CaCCs 
inhibitors does not reduce tactile allodynia. Time‑course of the effect of 
local peripheral administration of NFA (300 μg), T16Ainh‑A01 (10 μg) and 
CaCCinh‑A01 (10 μg) in rats subjected to L5/L6 spinal nerve ligation. With‑
drawal threshold was assessed 14 days after spinal nerve injury. Data are 
presented as the mean ± SEM for 6 animals. *Significantly different from 
the vehicle group (p<0.05), as determined by repeated measures two‑way 
ANOVA followed by the Bonferroni test.
Additional file 2: Figure S2. Intrathecal injection of CaCCs inhibitors in 
sham‑operated rats does not affect withdrawal threshold. Time‑course of 
the effect of intrathecal injection of NFA (300 μg), T16Ainh‑A01 (10 μg) 
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9‑AC: anthracene‑9‑carboxylic acid; ANOVA: analysis of variance; CaCCs: 
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